Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib with Cyclophosphamide and Dexamethasone in Untreated Multiple Myeloma or AL Amyloidosis
NCT01864018Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2013
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in multiple myeloma (MM) and light-chain amyloidosis, sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose of Cyclophosphamide at 28 days, Complete Response or Very Good Partial Response Rate up to 48 weeks and 1 more. Started Aug 2013; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT01864018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864018.